2018-2023 Global Pulmonary Hypertension Drug Consumption Market Report

Publisher Name :
Date: 11-Oct-2018
No. of pages: 133

In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Pulmonary Hypertension Drug market for 2018-2023.

Pulmonary hypertension is a state of the body in which the blood pressure rises in the arteries. Pulmonary hypertension drugs belong to the class of anti-hypertensives drugs that are used specifically to treat pulmonary hypertension. In addition, this class of drugs treats other life-threatening diseases such as arrhythmias, ryanoids syndrome, cephalagra, and angina.

Over the next five years, LPI(LP Information) projects that Pulmonary Hypertension Drug will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017.

This report presents a comprehensive overview, market shares, and growth opportunities of Pulmonary Hypertension Drug market by product type, application, key manufacturers and key regions.

To calculate the market size, LP Information considers value and volume generated from the sales of the following segments:

Segmentation by product type:

- Prostacyclin and Prostacyclin Analogs

- Endothelin Receptor Antagonists

- Phosphodiesterase-5 Inhibitors

- Soluble Guanylate Cyclase Stimulators

Segmentation by application:

- Early-stage Drug Candidates (Phase I & Phase II)

- Late-stage Drug Candidates (Phase III & Registration Phase)

This report also splits the market by region:

- Americas

- - United States

- - Canada

- - Mexico

- - Brazil

- APAC

- - China

- - Japan

- - Korea

- - Southeast Asia

- - India

- - Australia

- Europe

- - Germany

- - France

- - UK

- - Italy

- - Russia

- - Spain

- Middle East & Africa

- - Egypt

- - South Africa

- - Israel

- - Turkey

- - GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:

- GlaxoSmithKline plc

- Novartis AG

- Merck & Co., Inc.

- Abbott Laboratories

- Boehringer Ingelheim GmbH

- AstraZeneca plc

- F. Hoffmann-La Roche AG

- Teva Pharmaceutical Industries Ltd.

- Vectura Group plc

- Pfizer Inc.

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives

- To study and analyze the global Pulmonary Hypertension Drug consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.

- To understand the structure of Pulmonary Hypertension Drug market by identifying its various subsegments.

- Focuses on the key global Pulmonary Hypertension Drug manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

- To analyze the Pulmonary Hypertension Drug with respect to individual growth trends, future prospects, and their contribution to the total market.

- To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

- To project the consumption of Pulmonary Hypertension Drug submarkets, with respect to key regions (along with their respective key countries).

- To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

- To strategically profile the key players and comprehensively analyze their growth strategies.

2018-2023 Global Pulmonary Hypertension Drug Consumption Market Report

Table of Contents

2018-2023 Global Pulmonary Hypertension Drug Consumption Market Report

1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Pulmonary Hypertension Drug Consumption 2013-2023
2.1.2 Pulmonary Hypertension Drug Consumption CAGR by Region
2.2 Pulmonary Hypertension Drug Segment by Type
2.2.1 Prostacyclin and Prostacyclin Analogs
2.2.2 Endothelin Receptor Antagonists
2.2.3 Phosphodiesterase-5 Inhibitors
2.2.4 Soluble Guanylate Cyclase Stimulators
2.3 Pulmonary Hypertension Drug Consumption by Type
2.3.1 Global Pulmonary Hypertension Drug Consumption Market Share by Type (2013-2018)
2.3.2 Global Pulmonary Hypertension Drug Revenue and Market Share by Type (2013-2018)
2.3.3 Global Pulmonary Hypertension Drug Sale Price by Type (2013-2018)
2.4 Pulmonary Hypertension Drug Segment by Application
2.4.1 Early-stage Drug Candidates (Phase I & Phase II)
2.4.2 Late-stage Drug Candidates (Phase III & Registration Phase)
2.5 Pulmonary Hypertension Drug Consumption by Application
2.5.1 Global Pulmonary Hypertension Drug Consumption Market Share by Application (2013-2018)
2.5.2 Global Pulmonary Hypertension Drug Value and Market Share by Application (2013-2018)
2.5.3 Global Pulmonary Hypertension Drug Sale Price by Application (2013-2018)

3 Global Pulmonary Hypertension Drug by Players
3.1 Global Pulmonary Hypertension Drug Sales Market Share by Players
3.1.1 Global Pulmonary Hypertension Drug Sales by Players (2016-2018)
3.1.2 Global Pulmonary Hypertension Drug Sales Market Share by Players (2016-2018)
3.2 Global Pulmonary Hypertension Drug Revenue Market Share by Players
3.2.1 Global Pulmonary Hypertension Drug Revenue by Players (2016-2018)
3.2.2 Global Pulmonary Hypertension Drug Revenue Market Share by Players (2016-2018)
3.3 Global Pulmonary Hypertension Drug Sale Price by Players
3.4 Global Pulmonary Hypertension Drug Manufacturing Base Distribution, Sales Area, Product Types by Players
3.4.1 Global Pulmonary Hypertension Drug Manufacturing Base Distribution and Sales Area by Players
3.4.2 Players Pulmonary Hypertension Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Pulmonary Hypertension Drug by Regions
4.1 Pulmonary Hypertension Drug by Regions
4.1.1 Global Pulmonary Hypertension Drug Consumption by Regions
4.1.2 Global Pulmonary Hypertension Drug Value by Regions
4.2 Americas Pulmonary Hypertension Drug Consumption Growth
4.3 APAC Pulmonary Hypertension Drug Consumption Growth
4.4 Europe Pulmonary Hypertension Drug Consumption Growth
4.5 Middle East & Africa Pulmonary Hypertension Drug Consumption Growth

5 Americas
5.1 Americas Pulmonary Hypertension Drug Consumption by Countries
5.1.1 Americas Pulmonary Hypertension Drug Consumption by Countries (2013-2018)
5.1.2 Americas Pulmonary Hypertension Drug Value by Countries (2013-2018)
5.2 Americas Pulmonary Hypertension Drug Consumption by Type
5.3 Americas Pulmonary Hypertension Drug Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries

6 APAC
6.1 APAC Pulmonary Hypertension Drug Consumption by Countries
6.1.1 APAC Pulmonary Hypertension Drug Consumption by Countries (2013-2018)
6.1.2 APAC Pulmonary Hypertension Drug Value by Countries (2013-2018)
6.2 APAC Pulmonary Hypertension Drug Consumption by Type
6.3 APAC Pulmonary Hypertension Drug Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries

7 Europe
7.1 Europe Pulmonary Hypertension Drug by Countries
7.1.1 Europe Pulmonary Hypertension Drug Consumption by Countries (2013-2018)
7.1.2 Europe Pulmonary Hypertension Drug Value by Countries (2013-2018)
7.2 Europe Pulmonary Hypertension Drug Consumption by Type
7.3 Europe Pulmonary Hypertension Drug Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa
8.1 Middle East & Africa Pulmonary Hypertension Drug by Countries
8.1.1 Middle East & Africa Pulmonary Hypertension Drug Consumption by Countries (2013-2018)
8.1.2 Middle East & Africa Pulmonary Hypertension Drug Value by Countries (2013-2018)
8.2 Middle East & Africa Pulmonary Hypertension Drug Consumption by Type
8.3 Middle East & Africa Pulmonary Hypertension Drug Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.2 Pulmonary Hypertension Drug Distributors
10.3 Pulmonary Hypertension Drug Customer

11 Global Pulmonary Hypertension Drug Market Forecast
11.1 Global Pulmonary Hypertension Drug Consumption Forecast (2018-2023)
11.2 Global Pulmonary Hypertension Drug Forecast by Regions
11.2.1 Global Pulmonary Hypertension Drug Forecast by Regions (2018-2023)
11.2.2 Global Pulmonary Hypertension Drug Value Forecast by Regions (2018-2023)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.5.6 Spain Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Pulmonary Hypertension Drug Forecast by Type
11.8 Global Pulmonary Hypertension Drug Forecast by Application

12 Key Players Analysis
12.1 GlaxoSmithKline plc
12.1.1 Company Details
12.1.2 Pulmonary Hypertension Drug Product Offered
12.1.3 GlaxoSmithKline plc Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
12.1.4 Main Business Overview
12.1.5 GlaxoSmithKline plc News
12.2 Novartis AG
12.2.1 Company Details
12.2.2 Pulmonary Hypertension Drug Product Offered
12.2.3 Novartis AG Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
12.2.4 Main Business Overview
12.2.5 Novartis AG News
12.3 Merck & Co., Inc.
12.3.1 Company Details
12.3.2 Pulmonary Hypertension Drug Product Offered
12.3.3 Merck & Co., Inc. Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
12.3.4 Main Business Overview
12.3.5 Merck & Co., Inc. News
12.4 Abbott Laboratories
12.4.1 Company Details
12.4.2 Pulmonary Hypertension Drug Product Offered
12.4.3 Abbott Laboratories Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
12.4.4 Main Business Overview
12.4.5 Abbott Laboratories News
12.5 Boehringer Ingelheim GmbH
12.5.1 Company Details
12.5.2 Pulmonary Hypertension Drug Product Offered
12.5.3 Boehringer Ingelheim GmbH Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
12.5.4 Main Business Overview
12.5.5 Boehringer Ingelheim GmbH News
12.6 AstraZeneca plc
12.6.1 Company Details
12.6.2 Pulmonary Hypertension Drug Product Offered
12.6.3 AstraZeneca plc Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
12.6.4 Main Business Overview
12.6.5 AstraZeneca plc News
12.7 F. Hoffmann-La Roche AG
12.7.1 Company Details
12.7.2 Pulmonary Hypertension Drug Product Offered
12.7.3 F. Hoffmann-La Roche AG Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
12.7.4 Main Business Overview
12.7.5 F. Hoffmann-La Roche AG News
12.8 Teva Pharmaceutical Industries Ltd.
12.8.1 Company Details
12.8.2 Pulmonary Hypertension Drug Product Offered
12.8.3 Teva Pharmaceutical Industries Ltd. Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
12.8.4 Main Business Overview
12.8.5 Teva Pharmaceutical Industries Ltd. News
12.9 Vectura Group plc
12.9.1 Company Details
12.9.2 Pulmonary Hypertension Drug Product Offered
12.9.3 Vectura Group plc Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
12.9.4 Main Business Overview
12.9.5 Vectura Group plc News
12.10 Pfizer Inc.
12.10.1 Company Details
12.10.2 Pulmonary Hypertension Drug Product Offered
12.10.3 Pfizer Inc. Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
12.10.4 Main Business Overview
12.10.5 Pfizer Inc. News

13 Research Findings and Conclusion

List of Tables and Figures

Figure Picture of Pulmonary Hypertension Drug
Table Product Specifications of Pulmonary Hypertension Drug
Figure Pulmonary Hypertension Drug Report Years Considered
Figure Market Research Methodology
Figure Global Pulmonary Hypertension Drug Consumption Growth Rate 2013-2023 (MT)
Figure Global Pulmonary Hypertension Drug Value Growth Rate 2013-2023 ($ Millions)
Table Pulmonary Hypertension Drug Consumption CAGR by Region 2013-2023 ($ Millions)
Figure Product Picture of Prostacyclin and Prostacyclin Analogs
Table Major Players of Prostacyclin and Prostacyclin Analogs
Figure Product Picture of Endothelin Receptor Antagonists
Table Major Players of Endothelin Receptor Antagonists
Figure Product Picture of Phosphodiesterase-5 Inhibitors
Table Major Players of Phosphodiesterase-5 Inhibitors
Figure Product Picture of Soluble Guanylate Cyclase Stimulators
Table Major Players of Soluble Guanylate Cyclase Stimulators
Table Global Consumption Sales by Type (2013-2018)
Table Global Pulmonary Hypertension Drug Consumption Market Share by Type (2013-2018)
Figure Global Pulmonary Hypertension Drug Consumption Market Share by Type (2013-2018)
Table Global Pulmonary Hypertension Drug Revenue by Type (2013-2018) ($ million)
Table Global Pulmonary Hypertension Drug Value Market Share by Type (2013-2018) ($ Millions)
Figure Global Pulmonary Hypertension Drug Value Market Share by Type (2013-2018)
Table Global Pulmonary Hypertension Drug Sale Price by Type (2013-2018)
Figure Pulmonary Hypertension Drug Consumed in Early-stage Drug Candidates (Phase I & Phase II)
Figure Global Pulmonary Hypertension Drug Market: Early-stage Drug Candidates (Phase I & Phase II) (2013-2018) (MT)
Figure Global Pulmonary Hypertension Drug Market: Early-stage Drug Candidates (Phase I & Phase II) (2013-2018) ($ Millions)
Figure Global Early-stage Drug Candidates (Phase I & Phase II) YoY Growth ($ Millions)
Figure Pulmonary Hypertension Drug Consumed in Late-stage Drug Candidates (Phase III & Registration Phase)
Figure Global Pulmonary Hypertension Drug Market: Late-stage Drug Candidates (Phase III & Registration Phase) (2013-2018) (MT)
Figure Global Pulmonary Hypertension Drug Market: Late-stage Drug Candidates (Phase III & Registration Phase) (2013-2018) ($ Millions)
Figure Global Late-stage Drug Candidates (Phase III & Registration Phase) YoY Growth ($ Millions)
Table Global Consumption Sales by Application (2013-2018)
Table Global Pulmonary Hypertension Drug Consumption Market Share by Application (2013-2018)
Figure Global Pulmonary Hypertension Drug Consumption Market Share by Application (2013-2018)
Table Global Pulmonary Hypertension Drug Value by Application (2013-2018)
Table Global Pulmonary Hypertension Drug Value Market Share by Application (2013-2018)
Figure Global Pulmonary Hypertension Drug Value Market Share by Application (2013-2018)
Table Global Pulmonary Hypertension Drug Sale Price by Application (2013-2018)
Table Global Pulmonary Hypertension Drug Sales by Players (2016-2018) (MT)
Table Global Pulmonary Hypertension Drug Sales Market Share by Players (2016-2018)
Figure Global Pulmonary Hypertension Drug Sales Market Share by Players in 2016
Figure Global Pulmonary Hypertension Drug Sales Market Share by Players in 2017
Table Global Pulmonary Hypertension Drug Revenue by Players (2016-2018) ($ Millions)
Table Global Pulmonary Hypertension Drug Revenue Market Share by Players (2016-2018)
Figure Global Pulmonary Hypertension Drug Revenue Market Share by Players in 2016
Figure Global Pulmonary Hypertension Drug Revenue Market Share by Players in 2017
Table Global Pulmonary Hypertension Drug Sale Price by Players (2016-2018)
Figure Global Pulmonary Hypertension Drug Sale Price by Players in 2017
Table Global Pulmonary Hypertension Drug Manufacturing Base Distribution and Sales Area by Players
Table Players Pulmonary Hypertension Drug Products Offered
Table Pulmonary Hypertension Drug Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
Table Global Pulmonary Hypertension Drug Consumption by Regions 2013-2018 (MT)
Table Global Pulmonary Hypertension Drug Consumption Market Share by Regions 2013-2018
Figure Global Pulmonary Hypertension Drug Consumption Market Share by Regions 2013-2018
Table Global Pulmonary Hypertension Drug Value by Regions 2013-2018 ($ Millions)
Table Global Pulmonary Hypertension Drug Value Market Share by Regions 2013-2018
Figure Global Pulmonary Hypertension Drug Value Market Share by Regions 2013-2018
Figure Americas Pulmonary Hypertension Drug Consumption 2013-2018 (MT)
Figure Americas Pulmonary Hypertension Drug Value 2013-2018 ($ Millions)
Figure APAC Pulmonary Hypertension Drug Consumption 2013-2018 (MT)
Figure APAC Pulmonary Hypertension Drug Value 2013-2018 ($ Millions)
Figure Europe Pulmonary Hypertension Drug Consumption 2013-2018 (MT)
Figure Europe Pulmonary Hypertension Drug Value 2013-2018 ($ Millions)
Figure Middle East & Africa Pulmonary Hypertension Drug Consumption 2013-2018 (MT)
Figure Middle East & Africa Pulmonary Hypertension Drug Value 2013-2018 ($ Millions)
Table Americas Pulmonary Hypertension Drug Consumption by Countries (2013-2018) (MT)
Table Americas Pulmonary Hypertension Drug Consumption Market Share by Countries (2013-2018)
Figure Americas Pulmonary Hypertension Drug Consumption Market Share by Countries in 2017
Table Americas Pulmonary Hypertension Drug Value by Countries (2013-2018) ($ Millions)
Table Americas Pulmonary Hypertension Drug Value Market Share by Countries (2013-2018)
Figure Americas Pulmonary Hypertension Drug Value Market Share by Countries in 2017
Table Americas Pulmonary Hypertension Drug Consumption by Type (2013-2018) (MT)
Table Americas Pulmonary Hypertension Drug Consumption Market Share by Type (2013-2018)
Figure Americas Pulmonary Hypertension Drug Consumption Market Share by Type in 2017
Table Americas Pulmonary Hypertension Drug Consumption by Application (2013-2018) (MT)
Table Americas Pulmonary Hypertension Drug Consumption Market Share by Application (2013-2018)
Figure Americas Pulmonary Hypertension Drug Consumption Market Share by Application in 2017
Figure United States Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure United States Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Figure Canada Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure Canada Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Figure Mexico Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure Mexico Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Table APAC Pulmonary Hypertension Drug Consumption by Countries (2013-2018) (MT)
Table APAC Pulmonary Hypertension Drug Consumption Market Share by Countries (2013-2018)
Figure APAC Pulmonary Hypertension Drug Consumption Market Share by Countries in 2017
Table APAC Pulmonary Hypertension Drug Value by Countries (2013-2018) ($ Millions)
Table APAC Pulmonary Hypertension Drug Value Market Share by Countries (2013-2018)
Figure APAC Pulmonary Hypertension Drug Value Market Share by Countries in 2017
Table APAC Pulmonary Hypertension Drug Consumption by Type (2013-2018) (MT)
Table APAC Pulmonary Hypertension Drug Consumption Market Share by Type (2013-2018)
Figure APAC Pulmonary Hypertension Drug Consumption Market Share by Type in 2017
Table APAC Pulmonary Hypertension Drug Consumption by Application (2013-2018) (MT)
Table APAC Pulmonary Hypertension Drug Consumption Market Share by Application (2013-2018)
Figure APAC Pulmonary Hypertension Drug Consumption Market Share by Application in 2017
Figure China Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure China Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Figure Japan Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure Japan Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Figure Korea Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure Korea Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Figure Southeast Asia Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure Southeast Asia Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Figure India Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure India Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Figure Australia Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure Australia Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Table Europe Pulmonary Hypertension Drug Consumption by Countries (2013-2018) (MT)
Table Europe Pulmonary Hypertension Drug Consumption Market Share by Countries (2013-2018)
Figure Europe Pulmonary Hypertension Drug Consumption Market Share by Countries in 2017
Table Europe Pulmonary Hypertension Drug Value by Countries (2013-2018) ($ Millions)
Table Europe Pulmonary Hypertension Drug Value Market Share by Countries (2013-2018)
Figure Europe Pulmonary Hypertension Drug Value Market Share by Countries in 2017
Table Europe Pulmonary Hypertension Drug Consumption by Type (2013-2018) (MT)
Table Europe Pulmonary Hypertension Drug Consumption Market Share by Type (2013-2018)
Figure Europe Pulmonary Hypertension Drug Consumption Market Share by Type in 2017
Table Europe Pulmonary Hypertension Drug Consumption by Application (2013-2018) (MT)
Table Europe Pulmonary Hypertension Drug Consumption Market Share by Application (2013-2018)
Figure Europe Pulmonary Hypertension Drug Consumption Market Share by Application in 2017
Figure Germany Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure Germany Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Figure France Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure France Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Figure UK Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure UK Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Figure Italy Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure Italy Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Figure Russia Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure Russia Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Figure Spain Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure Spain Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Table Middle East & Africa Pulmonary Hypertension Drug Consumption by Countries (2013-2018) (MT)
Table Middle East & Africa Pulmonary Hypertension Drug Consumption Market Share by Countries (2013-2018)
Figure Middle East & Africa Pulmonary Hypertension Drug Consumption Market Share by Countries in 2017
Table Middle East & Africa Pulmonary Hypertension Drug Value by Countries (2013-2018) ($ Millions)
Table Middle East & Africa Pulmonary Hypertension Drug Value Market Share by Countries (2013-2018)
Figure Middle East & Africa Pulmonary Hypertension Drug Value Market Share by Countries in 2017
Table Middle East & Africa Pulmonary Hypertension Drug Consumption by Type (2013-2018) (MT)
Table Middle East & Africa Pulmonary Hypertension Drug Consumption Market Share by Type (2013-2018)
Figure Middle East & Africa Pulmonary Hypertension Drug Consumption Market Share by Type in 2017
Table Middle East & Africa Pulmonary Hypertension Drug Consumption by Application (2013-2018) (MT)
Table Middle East & Africa Pulmonary Hypertension Drug Consumption Market Share by Application (2013-2018)
Figure Middle East & Africa Pulmonary Hypertension Drug Consumption Market Share by Application in 2017
Figure Egypt Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure Egypt Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Figure South Africa Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure South Africa Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Figure Israel Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure Israel Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Figure Turkey Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure Turkey Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Figure GCC Countries Pulmonary Hypertension Drug Consumption Growth 2013-2018 (MT)
Figure GCC Countries Pulmonary Hypertension Drug Value Growth 2013-2018 ($ Millions)
Table Pulmonary Hypertension Drug Distributors List
Table Pulmonary Hypertension Drug Customer List
Figure Global Pulmonary Hypertension Drug Consumption Growth Rate Forecast (2018-2023) (MT)
Figure Global Pulmonary Hypertension Drug Value Growth Rate Forecast (2018-2023) ($ Millions)
Table Global Pulmonary Hypertension Drug Consumption Forecast by Countries (2018-2023) (MT)
Table Global Pulmonary Hypertension Drug Consumption Market Forecast by Regions
Table Global Pulmonary Hypertension Drug Value Forecast by Countries (2018-2023) ($ Millions)
Table Global Pulmonary Hypertension Drug Value Market Share Forecast by Regions
Figure Americas Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Americas Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure APAC Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure APAC Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure Europe Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Europe Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure Middle East & Africa Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Middle East & Africa Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure United States Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure United States Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure Canada Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Canada Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure Mexico Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Mexico Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure Brazil Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Brazil Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure China Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure China Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure Japan Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Japan Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure Korea Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Korea Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure Southeast Asia Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Southeast Asia Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure India Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure India Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure Australia Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Australia Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure Germany Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Germany Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure France Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure France Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure UK Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure UK Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure Italy Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Italy Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure Russia Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Russia Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure Spain Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Spain Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure Egypt Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Egypt Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure South Africa Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure South Africa Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure Israel Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Israel Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure Turkey Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure Turkey Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Figure GCC Countries Pulmonary Hypertension Drug Consumption 2018-2023 (MT)
Figure GCC Countries Pulmonary Hypertension Drug Value 2018-2023 ($ Millions)
Table Global Pulmonary Hypertension Drug Consumption Forecast by Type (2018-2023) (MT)
Table Global Pulmonary Hypertension Drug Consumption Market Share Forecast by Type (2018-2023)
Table Global Pulmonary Hypertension Drug Value Forecast by Type (2018-2023) ($ Millions)
Table Global Pulmonary Hypertension Drug Value Market Share Forecast by Type (2018-2023)
Table Global Pulmonary Hypertension Drug Consumption Forecast by Application (2018-2023) (MT)
Table Global Pulmonary Hypertension Drug Consumption Market Share Forecast by Application (2018-2023)
Table Global Pulmonary Hypertension Drug Value Forecast by Application (2018-2023) ($ Millions)
Table Global Pulmonary Hypertension Drug Value Market Share Forecast by Application (2018-2023)
Table GlaxoSmithKline plc Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table GlaxoSmithKline plc Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
Figure GlaxoSmithKline plc Pulmonary Hypertension Drug Market Share (2016-2018)
Table Novartis AG Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Novartis AG Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Novartis AG Pulmonary Hypertension Drug Market Share (2016-2018)
Table Merck & Co., Inc. Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Merck & Co., Inc. Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Merck & Co., Inc. Pulmonary Hypertension Drug Market Share (2016-2018)
Table Abbott Laboratories Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Abbott Laboratories Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Abbott Laboratories Pulmonary Hypertension Drug Market Share (2016-2018)
Table Boehringer Ingelheim GmbH Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Boehringer Ingelheim GmbH Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Boehringer Ingelheim GmbH Pulmonary Hypertension Drug Market Share (2016-2018)
Table AstraZeneca plc Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table AstraZeneca plc Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
Figure AstraZeneca plc Pulmonary Hypertension Drug Market Share (2016-2018)
Table F. Hoffmann-La Roche AG Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table F. Hoffmann-La Roche AG Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
Figure F. Hoffmann-La Roche AG Pulmonary Hypertension Drug Market Share (2016-2018)
Table Teva Pharmaceutical Industries Ltd. Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Teva Pharmaceutical Industries Ltd. Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Teva Pharmaceutical Industries Ltd. Pulmonary Hypertension Drug Market Share (2016-2018)
Table Vectura Group plc Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Vectura Group plc Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Vectura Group plc Pulmonary Hypertension Drug Market Share (2016-2018)
Table Pfizer Inc. Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Pfizer Inc. Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Pfizer Inc. Pulmonary Hypertension Drug Market Share (2016-2018)
  • Global White Willow Bark Extract Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 19-Nov-2018        Price: US 3480 Onwards        Pages: 117
    White willow bark is used for the treatment of pain such as lower back and osteoarthritis in regions of Asia and Europe. Scope of the Report: White willow bark extract is slowly gaining popularity and is expected to show a steady increase in the revenue growth. The worldwide market for White Willow Bark Extract is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR ......
  • Global Wintergreen Oil Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 19-Nov-2018        Price: US 3480 Onwards        Pages: 121
    Wintergreen oil is of high importance and has a high reputation since ages as it possesses various therapeutic properties such as anti-rheumatic, anti-arthritic, antiseptic, aromatic, analgesic properties, etc. Scope of the Report: Due to change in the market trend, people are more interested in natural products which will play an important role in fueling the growth of present Wintergreen Oil Market. The worldwide market for Wintergreen Oil is expected to grow at a ......
  • Global Irritable Bowel Syndrome Treatment Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 19-Nov-2018        Price: US 3480 Onwards        Pages: 115
    Irritable bowel syndrome is a functional gastrointestinal disorder of gut that may be characterized by colon muscle contractions. Irritable bowel syndrome is a common disorder. There is no complete cure for the irritable bowel syndrome. Medicines used in irritable bowel syndrome are effective in decreasing the symptoms. Scope of the Report: Increased awareness about available treatment among the patients, medical community is one of the major driver in global irritable bowe......
  • Global Peppermint Oil Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 19-Nov-2018        Price: US 3480 Onwards        Pages: 120
    Peppermint Oil is the oil that is extracted from the stem and flowers of the peppermint herb. Scope of the Report: This report focuses on the Peppermint Oil in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. The worldwide market for Peppermint Oil is expected to grow at a CAGR of roughly xx% over the next five years, wi......
  • Global Dermal Adhesives Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 19-Nov-2018        Price: US 3480 Onwards        Pages: 120
    A dermal adhesive (or skin glue) is a glue used to close wounds in the skin, as an alternative to sutures, staples or clips. Scope of the Report: Glued closure produces less scarring and is less prone to infection than sutured or stapled closure. There is also no residual closure to remove, so follow-up visits for removal are not required. The factor that contributes to the growth of the global Skin Glue market is the rising number of traumatic injuries. The market g......
  • Global Skin Glue Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 19-Nov-2018        Price: US 3480 Onwards        Pages: 123
    A dermal adhesive (or skin glue) is a glue used to close wounds in the skin, as an alternative to sutures, staples or clips. Scope of the Report: Glued closure produces less scarring and is less prone to infection than sutured or stapled closure. There is also no residual closure to remove, so follow-up visits for removal are not required. The factor that contributes to the growth of the global Skin Glue market is the rising number of traumatic injuries. The market g......
  • Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 19-Nov-2018        Price: US 3480 Onwards        Pages: 124
    Dipeptide Peptidase 4 (DPP-4) Inhibitors are a class of oral diabetes drugs that work by blocking the action of DPP-4, an enzyme which destroys a group of gastrointestinal hormones called incretins. Incretins help stimulate the production of insulin when it is needed (e.g. after eating) and reduce the production of glucagon by the liver when it is not needed (e.g. during digestion). They also slow down digestion and decrease appetite. So by protecting incretins from damage, DPP-4 inhibitors help......
  • Global Alpha Glucosidase Inhibitors Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 19-Nov-2018        Price: US 3480 Onwards        Pages: 124
    Alpha-glucosidase is an enzyme that is inhibited by alpha-glucosidase inhibitor drugs. Alpha-glucosidase helps in absorption of carbohydrates by breaking down carbohydrates into tiny sugar molecules such as glucose. The inhibition is reversible, and competitive inhibition. Alpha-glucosidase inhibitor drugs help in delaying glucose absorption and slow the digestion of carbohydrates. This results in lower rise of glucose in the blood after meals and remains effective throughout the day. ......
  • Global Cancer Pain Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 19-Nov-2018        Price: US 3480 Onwards        Pages: 120
    Pain in cancer may come from compressing or infiltrating nearby body parts, from treatments and diagnostic procedures or from skin, nerve, and the other changes caused by a hormone imbalance or immune response. Scope of the Report: The report, states that opioids will continue to dominate as a breakthrough cancer pain treatment, mostly due to available generics and physician familiarity. The worldwide market for Cancer Pain is expected to grow at a CAGR of roughly xx......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs